content_image/1043491.jpg content_image/1043487.jpg content_image/1043488.jpg
Future lease payments for non-cancellable operating leases as of December 31, 2020 were as follows: 

<img src='content_image/1043491.jpg'>

Right-of-use assets obtained in exchange for new operating lease obligations were $326 million in 2020 which includes $82 million of right-of-use assets acquired in the MyoKardia acquisition. Cash paid for amounts included in the measurement of operating lease liabilities was $164 million in 2020 and $79 million in 2019. Cash paid in 2019 was net of a $33 million lease incentive received. 

Undiscounted lease obligations for operating leases not yet commenced were approximately $750 million as of December 31, 2020. The obligation primarily relates to a research and development facility that is being constructed by the lessor and which is expected to be ready for use in 2022. 

A right-of-use asset impairment charge of $31 million was incurred during 2020 due to a site vacancy and partial sublease. The fair value of the right- of-use asset was determined using an income approach incorporating potential future cash flows associated with the sublease of the building. 

Supplemental balance sheet information related to leases was as follows: 

<img src='content_image/1043487.jpg'>

## Note 14. GOODWILL AND OTHER INTANGIBLE ASSETS 

<img src='content_image/1043488.jpg'>

(a) Includes measurement period adjustments. Refer to “—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements” for more information. 

In 2020, $13.1 billion of IPRD was reclassified to acquired marketed product rights upon approval in the U.S. for Reblozyl  for the treatment of anemia in adults with lower-risk MDS, Zeposia  and Onureg . Amortization expense of other intangible assets was $9.9 billion in 2020, $1.3 billion in 2019 and $198 million in 2018. Future annual amortization expense of other intangible assets is expected to be approximately $10.2 billion in 2021, $10.1 billion in 2022, $9.5 billion in 2023 $8.5 billion in 2024 and $1.2 billion in 2025. 

Other intangible asset impairment charges were $1.1 billion in 2020, $66 million in 2019 and $84 million in 2018, respectively. 

